Compare GAUZ & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | SNTI |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 24.5M |
| IPO Year | 2019 | 2021 |
| Metric | GAUZ | SNTI |
|---|---|---|
| Price | $0.72 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.50 | $8.50 |
| AVG Volume (30 Days) | ★ 239.7K | 96.6K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $59.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $0.77 |
| 52 Week High | $10.76 | $5.10 |
| Indicator | GAUZ | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 45.84 |
| Support Level | $0.48 | $0.78 |
| Resistance Level | $1.00 | $1.02 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 32.50 | 46.34 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.